The control of gastrointestinal nematodes (GINs) in small ruminants is principally dependent on anthelmintic therapy, which encounters the rising problem of anthelmintic resistance (AR) development. Veterinarians reported anthelmintic failure in several sheep farms in Arbat District, Sulaymaniyah, northern Iraq, which called for a systematic study about the efficacy of three commonly used drugs: albendazole, ivermectin, and levamisole.

A three-month-old female New Zealand White Rabbit, weighing about 1.4 kg was brought to the Veterinary Clinical Complex, Veterinary College and Research Institute, Tirunelveli with ahistory of intense pruritis and alopecia all over the body. Clinical observation revealed crusty lesions on the nose,ear margin and toes. Microscopic examination of the deep skin scraping revealed the presence of Psoroptes cuniculi mite. The rabbit was treated with an injection Ivermectin @ 0.4 mg/kg sub-cutaneous and an injection of Chlorpheniramine maleate @ 0.4 mg/kg intramuscular and further advised the owner to give HITEK® oral solution (Ivermectin) @ 0.4 mg/kg PO once a week and Benzyl benzoate I.P. solution topically daily for a continuous period of one month along with multivitamin supplementation (Multistar pet®) @ 2 ml PO BID. The rabbit recovered successfully without any drug side effects (Tandem usage of ivermectin and Benzyl Benzoate).

A female Ongole calf aged one year and nine months was found to have nodular development around the left eye and neck region. Clinical examination revealed that the calf had cutaneous papilloma (wart), which was treated with autohemotherapy, ivermectin and levamisole injections along with placement of a ligature around wart's base. On the third day of treatment, a large papilloma on the left lower eyelid dried up and sloughed off. On the tenth day of therapy, the warts on the upper eyelid and neck began to dry and flake off, leaving behind barely visible scars at the original growth sites. The animal underwent an uncomplicated recovery and completely recovered from the ailment.

This study presents two clinical cases in Chinchilla and Himalayan rabbits, exhibiting symptoms such as alopecia, skin lesions, and ear lesions. Skin scrapings and fecal samples were collected and processed, revealing the presence of Sarcoptes scabiei mites, Psoroptes cuniculi mites, and Eimeria oocysts. Treatment involved subcutaneous administration of Ivermectin (0.2 mg/kg), accompanied by supportive and topical application of Benzyl benzoate. The rabbits displayed clinical improvement, with complete recovery observed within 30 days.

An outbreak of chorioptic mange infestation was observed in a sheep and goat flock during 2021 in the Kandukur village of Anantapur district, with a history of skin itching, thick scabs and loss of hair. Skin lesions were characterized by alopecica, crusty scabs on hind limbs, face, ears and scrotal region. Microscopic examination of deep skin scrapings revealed the presence of Chorioptes spp mites. Affected sheep and goats were treated with Ivermectin injection (200 mg/kg. body wt) administered subcutaneously weekly once for 2 weeks along with dipping using Butox spray (Deltamethrin) and supportive therapy with brotone syrup (liver tonic). Examination of deep skin scraping two weeks post treatment found negative for the Chorioptes spp mites.

Antiviral activity of ivermectin was examined against R2B strain of Newcastle disease virus in 9 - day old embryonated chicken eggs. Five distinct concentrations (500, 250, 100, 50, 10 µg/mL) of ivermectin were used in the study. Haemagglutination test was performed to determine the antiviral activity of ivermectin by using chicken RBC. The results revealed that ivermectin can exert a significant antiviral activity against Newcastle disease virus at higher concentrations (500, 250 and 100 µg/ml) but with cytotoxic effects. On the contrary a moderate to weak antiviral activity without cytotoxicity was demonstrated at lower concentrations (50, 10 µg/ml).

There are limited data on the efficacy of antiparasitic treatments and husbandry methods to control nematode infections in captive populations of African green monkeys (AGMs), Chlorocebus sabaeus. In faecal egg count (FEC) tests, 10 of the 11 (91%) adult male AGMs captured from the large feral population on the island of St Kitts had evidence of nematode infections, mostly Capillaria (8/11, 73%), Trichuris trichiura (7/11, 64%) and strongylid species (7/11, 64%) specifically (hookworm and Trichostrongylus, 50/50), but also Strongyloides fuelleborni (1/11, 9%). When kept in individual cages with cleaning and feeding regimens to prevent reinfections and treated concurrently with ivermectin (300 µg/kg, given subcutaneously) and albendazole (10 mg/kg, given orally) daily for 3 days, 60% (6/10) of the AGMs were negative at a follow-up FEC at 3 months and by FEC and necropsy at the end of the study 5–8 months later. One monkey appeared to have been reinfected with T. trichiura after being negative by FEC at 3 months post-treatment. Four AGMs were positive for T. trichiura at the 3 month FEC follow-up but were negative at the end of the study after one further treatment regimen. Although initially being cleared of Capillaria following treatment, three AGMs were found to be infected at the end of the study. The ivermectin and albendazole treatment regimen coupled with good husbandry practices to prevent reinfections effectively controlled nematode infections in captive AGMs.

There are limited data on the efficacy of antiparasitic treatments and husbandry methods to control nematode infections in captive populations of African green monkeys (AGMs), Chlorocebus sabaeus. In faecal egg count (FEC) tests, 10 of the 11 (91%) adult male AGMs captured from the large feral population on the island of St Kitts had evidence of nematode infections, mostly Capillaria (8/11, 73%), Trichuris trichiura (7/11, 64%) and strongylid species (7/11, 64%) specifically (hookworm and Trichostrongylus, 50/50), but also Strongyloides fuelleborni (1/11, 9%). When kept in individual cages with cleaning and feeding regimens to prevent reinfections and treated concurrently with ivermectin (300 µg/kg, given subcutaneously) and albendazole (10 mg/kg, given orally) daily for 3 days, 60% (6/10) of the AGMs were negative at a follow-up FEC at 3 months and by FEC and necropsy at the end of the study 5-8 months later. One monkey appeared to have been reinfected with T. trichiura after being negative by FEC at 3 months post-treatment. Four AGMs were positive for T. trichiura at the 3 month FEC follow-up but were negative at the end of the study after one further treatment regimen. Although initially being cleared of Capillaria following treatment, three AGMs were found to be infected at the end of the study. The ivermectin and albendazole treatment regimen coupled with good husbandry practices to prevent reinfections effectively controlled nematode infections in captive AGMs.

Objective: To determine whether the reported drug-drug interaction between the flea medication spinosad and ivermectin is attributable to inhibition of P-glycoprotein by spinosad. Animals: 6 healthy adult dogs with the ABCB1 wildtype genotype. Procedures: The study was conducted as a prospective, masked, randomized crossover design. Six dogs were allocated to 2 groups; each dog served as its own control animal. Dogs in one of the groups received spinosad at the manufacturer's recommended dose; the other group received no treatment. Forty-eight hours later, scintigraphic imaging of the head and abdomen were performed with the radiolabeled P-glycoprotein substrate methoxy-isobutyl-isonitrile (sestamibi) in both groups of dogs. After a washout period of 60 days, the dogs in each group received the alternate treatment, and scintigraphic imaging again was performed 48 hours later. Gallbladder-to-liver and brain-to-neck musculature ratios of technetium Tc 99m sestamibi were calculated for each dog and compared between treatments. Results: No significant differences in gallbladder-to-liver or brain-to-neck musculature ratios were found between treatments. Conclusions and Clinical Relevance: Results provided evidence that spinosad did not inhibit P-glycoprotein function 48 hours after spinosad was administered at the manufacturer's recommended dose. Further investigations will be necessary to elucidate the mechanism of the reported toxic interaction between spinosad and ivermectin.

Objective: To develop in genetically engineered mice an alternative screening method for evaluation of P-glycoprotein substrate toxicosis in ivermectin-sensitive Collies. Animals: 14 wild-type C57BL/6J mice (controls) and 21 genetically engineered mice in which the abcb1a and abcb1b genes were disrupted and the mutated canine ABCB1 gene was inserted. Procedures: Mice were allocated to receive 10 mg of ivermectin/kg via SC injection (n = 30) or a vehicle-only formulation of propylene glycol and glycerol formal (5). Each was observed for clinical signs of toxic effects from 0 to 7 hours following drug administration. Results: After ivermectin administration, considerable differences were observed in drug sensitivity between the 2 types of mice. The genetically engineered mice with the mutated canine ABCB1 gene had signs of severe sensitivity to ivermectin, characterized by progressive lethargy, ataxia, and tremors, whereas the wild-type control mice developed no remarkable effects related to the ivermectin. Conclusions and Clinical Relevance: The ivermectin sensitivity modeled in the transgenic mice closely resembled the lethargy, stupor, disorientation, and loss of coordination observed in ivermectin-sensitive Collies with the ABCB1–1Δ mutation. As such, the model has the potential to facilitate toxicity assessments of certain drugs for dogs that are P-glycoprotein substrates, and it may serve to reduce the use of dogs in avermectin derivative safety studies that are part of the new animal drug approval process.